Role of soluble Fas ligand in autoimmune diseases

Li, Ningli; Nie, Hong; Yu, Qing; Zhang, Jiying; Ma, Anlun; Shen, Baihua; Wang, Li; Bai, Jun; Chen, Xuehua; Zhou, Tong; Zhang, Dongqing

doi:10.3748/wjg.v10.i21.3151

Cited by 22 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most common autoimmune diseases include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM) and Sjögren's syndrome (SS). Among these diseases, RA, SLE and SSc are believed to be autoimmune diseases induced by Th1 cells which can recognize auto-antigens may play role on special tissues [1][2][3][4][5]. For example, RA is a common disease characterized by chronic lesions of polyarthritis.…”

Section: Introductionmentioning

confidence: 98%

“…For example, RA is a common disease characterized by chronic lesions of polyarthritis. It has been commonly accepted that cell mediated immune responses are involved in chronic inflammation since T and B lymphocytes and antigen presenting cells are observed to be enriched in synovial fluid of RA patients [1]. Other example is SLE and it is also a prototypic autoimmune disease characterized by the production of antibodies to the components of cell nucleus [5].…”

Section: Introductionmentioning

confidence: 99%

“…The Fas molecule could occur as a soluble protein as well as surface receptor. The soluble Fas (sFas) is a secreted variant which lacks the transmembrane segment of the surface molecule and can be quantified in body fluids [1]. It has been suggested that sFas modifies ligand concentration, down regulates membrane receptor number, and specifically reduces ligand-receptor numbers, and specifically inhibits ligand-receptor association in the extracellular space, thus preventing the induction of apoptosis [4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum soluble Fas levels in patients with autoimmune rheumatic diseases

Şahin¹,

Aydıntuğ²,

Tunc³

et al. 2007

Clinical Biochemistry

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum soluble Fas levels in patients with autoimmune rheumatic diseases

Şahin¹,

Aydıntuğ²,

Tunc³

et al. 2007

Clinical Biochemistry

View full text Add to dashboard Cite

“…Moreover, sFasL has been shown to act as a direct neutrophil chemo-attractant in vitro. 4,5 In light of these concerns, dysregulated Fas/FasL system could be the cause of impaired apoptosis and neutrophil-mediated inflammatory response. High serum levels of sFasL were detected in patients with large granular T cell leukemia, large granular NK cell leukemia and autoimmune diseases.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, mutations in the Fas and Fas ligand have been detected in autoimmune and lymphoproliferative syndromes of human and mice. [4][5][6] Therefore, Fas/FasL system is an essential mechanism for the maintenance of apoptosis and immune homeostasis in a wide variety of tissues as well as activated immune cells, and this pathway plays an important role in the down-regulation of inflammatory responses. [1][2][3][4][5] Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disease characterized by self-limited recurrent episodes of fever and aseptic inflammation of serosal surfaces.…”

Section: Introductionmentioning

confidence: 99%

Serum soluble fas ligand levels in familial Mediterranean fever

Çeri¹,

Unverdi²,

Şeneş³

et al. 2013

Renal Failure

View full text Add to dashboard Cite

Introduction: Fas/FasL system plays an important role in the regulation of cell life and death, and circulating levels of sFasL have been shown to increase in some inflammatory conditions. However, there is no sufficient information about the levels of sFasL in patients with FMF. This study was designed to evaluate the serum sFasL levels in patients with FMF during attack and attack-free periods. Methods: Twenty-five FMF patients in attack and forty-four in free-attack period, and 20 age-, sex-, and BMI-matched healthy controls were included in this study. Participants with any chronic diseases were excluded. Blood samples were obtained within the first 24 h of the attack period and between febrile attacks, and levels of WBC, ESR, Fibrinogen, hsCRP and sFasL were determined. Results: The levels of traditional acute phase reactants during the attack were significantly higher than the attack-free and controls (p50.05). The serum sFasL levels in the FMF study groups did not differ from the control group (0.70 AE 0.08 vs. 0.73 AE 0.12; 0.70 AE 0.08 vs. 0.83 AE 0.14; 0.73 AE 0.12 vs. 0.83 AE 0.14, respectively, p40.05). Moreover, the sFasL levels during the attack were not significantly different from those in attack-free patients (0.70 AE 0.08 vs. 0.83 AE 0.14, p40.05). Conclusion: In this study, we demonstrated that serum sFasL levels were not markedly affected in FMF and cannot be used as a supportive marker to differentiate attacks from attack-free periods. However, further studies are needed to determine its usefulness as a marker in clinical practice.

show abstract

Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still’s disease

et al. 2006

View full text Add to dashboard Cite

To investigate serum levels of soluble Fas (sFas), soluble Fas ligand (sFas-L), and matrix metalloproteinase-3 (MMP-3) in patients with active untreated adult onset Still's disease (AOSD). Serum levels of sFas, sFas-L, and MMP-3 were determined by enzyme-linked immunosorbent assays in 20 patients with active untreated AOSD, 20 patients with active rheumatoid arthritis (RA), and 20 healthy controls. Linear regression was used to evaluate the correlation between clinical activity scores and serum levels of sFas, sFas-L, and MMP-3 in AOSD patients. Significantly higher levels of sFas, sFas-L, and MMP-3 in sera were found in active untreated AOSD patients compared to healthy controls. Serum levels of sFas, sFas-L, and MMP-3 correlated well with clinical activity scores of AOSD patients (r=0.467, 0.694, and 0.798, respectively). There was a significant correlation between CRP values and serum levels of sFas-L as well as MMP-3 (r=0.583 and r=0.582, respectively, both p<0.01), and a positive correlation between serum sFas-L levels and serum MMP-3 levels (r=0.726, p<0.001) in AOSD patients. Significantly higher levels of serum sFas-L were found in AOSD patients than in RA patients. Serum levels of sFas, sFas-L, and MMP-3 fluctuated and were found to be parallel to disease activity of AOSD. sFas, sFas-L, and MMP-3, which were significantly elevated in sera of active untreated AOSD patients and paralleled disease activity, may be involved in the pathogenesis of this disease. Further studies are needed to determine the pathophysiologic role of sFas, sFas-L, and MMP-3 in AOSD.

show abstract

Role of soluble Fas ligand in autoimmune diseases

Abstract: AIM:To investigate the role of soluble Fas ligand in autoimmune diseases.

Cited by 22 publications

References 22 publications

Serum soluble Fas levels in patients with autoimmune rheumatic diseases

Serum soluble Fas levels in patients with autoimmune rheumatic diseases

Serum soluble fas ligand levels in familial Mediterranean fever

Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still’s disease

Contact Info

Product

Resources

About